National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

When Jennifer Woyach, MD, started as a resident and fellow two decades ago, patients with chronic lymphocytic leukemia (CLL) ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

Eli Lilly’s Jaypirca (pirtobrutinib) has been recommended by the European Medicines Agency’s (EMA) human medicines committee ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...